Stephen Colagiuri. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Cost-Benefit AnalysisDiabetes Mellitus, Type 2/complicationsDiabetes Mellitus, Type 2/diagnosisDiabetes Mellitus, Type 2/economicsDiabetes Mellitus, Type 2/epidemiologyGlucose Intolerance/complicationsGlucose Intolerance/diagnosisGlucose Intolerance/economicsGlucose Intolerance/epidemiologyGlucose Tolerance Test/economicsGlucose Tolerance Test/statistics & numerical dataHealth Care Costs/statistics & numerical dataHealth Care Costs/trendsHumansHyperglycemia/complicationsHyperglycemia/diagnosisHyperglycemia/economicsHyperglycemia/epidemiologyMass Screening/economicsPrevalence
Year: 2012 PMID： 22682947 DOI： 10.1016/j.diabres.2012.05.012
Source DB: PubMed Journal: Diabetes Res Clin Pract ISSN： 0168-8227 Impact factor: 5.602